Cargando…
The cost of unresectable stage III or stage IV melanoma in Italy
BACKGROUND: In recent decades, melanoma incidence has been increasing in European countries; in 2006, there were approximately 60,000 cases leading to 13,000 deaths. Within Europe there is some geographical variation in the incidence of melanoma, with the highest rates reported in Scandinavia (15 ca...
Autores principales: | Maio, Michele, Ascierto, Paolo, Testori, Alessandro, Ridolfi, Ruggero, Bajetta, Emilio, Queirolo, Paola, Guida, Michele, Romanini, Antonella, Chiarion-Sileni, Vanna, Pigozzo, Jacopo, Di Giacomo, Anna Maria, Calandriello, Mario, Didoni, Guido, van Baardewijk, Marck, Konto, Cyril, Lucioni, Carlo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3542007/ https://www.ncbi.nlm.nih.gov/pubmed/23116062 http://dx.doi.org/10.1186/1756-9966-31-91 |
Ejemplares similares
-
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
por: Ascierto, Paolo A, et al.
Publicado: (2014) -
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme
por: Altomonte, Maresa, et al.
Publicado: (2013) -
Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]
por: Chiarion-Sileni, Vanna, et al.
Publicado: (2006) -
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
por: Queirolo, Paola, et al.
Publicado: (2014) -
Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial
por: Guida, Michele, et al.
Publicado: (2003)